These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 9079375)

  • 1. Solution conformation of an immunogenic peptide derived from the principal neutralizing determinant of the HIV-2 envelope glycoprotein gp125.
    Campbell AP; Sykes BD; Norrby E; Assa-Munt N; Dyson HJ
    Fold Des; 1996; 1(2):157-65. PubMed ID: 9079375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two neutralizing domains in the V3 region in the envelope glycoprotein gp125 of HIV type 2.
    Björling E; Chiodi F; Utter G; Norrby E
    J Immunol; 1994 Feb; 152(4):1952-9. PubMed ID: 8120399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Solution conformational preferences of immunogenic peptides derived from the principal neutralizing determinant of the HIV-1 envelope glycoprotein gp120.
    Chandrasekhar K; Profy AT; Dyson HJ
    Biochemistry; 1991 Sep; 30(38):9187-94. PubMed ID: 1892828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of neutralizing sites in the second variable and fourth variable region in gp125 and a conserved region in gp36 of human immunodeficiency virus type 2.
    Skott P; Achour A; Norin M; Thorstensson R; Björling E
    Viral Immunol; 1999; 12(1):79-88. PubMed ID: 10333245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antigenicity of linear and cyclic peptides mimicking the disulfide loops in HIV-2 envelope glycoprotein: synthesis, reoxidation and purification.
    Belhadj Jrad B; Bahraoui E
    J Pept Res; 1998 May; 51(5):370-85. PubMed ID: 9606017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperimmune antisera against synthetic peptides representing the glycoprotein of human immunodeficiency virus type 2 can mediate neutralization and antibody-dependent cytotoxic activity.
    Björling E; Broliden K; Bernardi D; Utter G; Thorstensson R; Chiodi F; Norrby E
    Proc Natl Acad Sci U S A; 1991 Jul; 88(14):6082-6. PubMed ID: 2068087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of monoclonal antibodies to human immunodeficiency virus type 2 envelope glycoproteins.
    Traincard F; Rey-Cuillé MA; Huon I; Dartevelle S; Mazié JC; Benichou S
    AIDS Res Hum Retroviruses; 1994 Dec; 10(12):1659-67. PubMed ID: 7888225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations.
    Ahlers JD; Pendleton CD; Dunlop N; Minassian A; Nara PL; Berzofsky JA
    J Immunol; 1993 Jun; 150(12):5647-65. PubMed ID: 8515081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Linear and cyclic peptides mimicking the disulfide loops in HIV-2 envelope glycoprotein induced antibodies with different specificity.
    Jrad BB; Bahraoui E
    Mol Immunol; 1997; 34(16-17):1177-89. PubMed ID: 9566765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of B-cell antigenic sites on HIV-2 gp125.
    Mannervik M; Putkonen P; Rudén U; Kent KA; Norrby E; Wahren B; Broliden PA
    J Acquir Immune Defic Syndr (1988); 1992; 5(2):177-87. PubMed ID: 1370692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-based design of a constrained peptide mimic of the HIV-1 V3 loop neutralization site.
    Ghiara JB; Ferguson DC; Satterthwait AC; Dyson HJ; Wilson IA
    J Mol Biol; 1997 Feb; 266(1):31-9. PubMed ID: 9054968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
    Borbe HC; Stuber G; Wagner R; Wolf H; Modrow S
    J Pept Sci; 1995; 1(2):109-23. PubMed ID: 9222988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epitope specificity of MHC restricted cytotoxic T lymphocytes induced by candidate HIV-1 vaccine.
    Johnson RP; Hammond SA; Trocha A; Siliciano RF; Walker BD
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S73-5. PubMed ID: 7532425
    [No Abstract]   [Full Text] [Related]  

  • 14. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of synthetic peptides corresponding to various epitopes of the human immunodeficiency virus envelope protein.
    Zaghouani H; Hall B; Shah H; Bona C
    Adv Exp Med Biol; 1991; 303():53-62. PubMed ID: 1725238
    [No Abstract]   [Full Text] [Related]  

  • 16. Fine characterization of a V3-region neutralizing epitope in human immunodeficiency virus type 2.
    Mörner A; Achour A; Norin M; Thorstensson R; Björling E
    Virus Res; 1999 Jan; 59(1):49-60. PubMed ID: 10854165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conformation of the principal neutralizing determinant of human immunodeficiency virus type 1 in complex with an anti-gp120 virus neutralizing antibody studied by two-dimensional nuclear magnetic resonance difference spectroscopy.
    Zvi A; Feigelson DJ; Hayek Y; Anglister J
    Biochemistry; 1997 Jul; 36(28):8619-27. PubMed ID: 9214308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptides containing multideterminant clusters of human immunodeficiency virus envelope induce murine and human T-cell responses in diverse histocompatibility types.
    Berzofsky JA; Pendleton CD; Clerici M; Ahlers J; Lucey DR; Putney SD; Shearer GM
    Trans Assoc Am Physicians; 1991; 104():69-77. PubMed ID: 1845157
    [No Abstract]   [Full Text] [Related]  

  • 19. Deletion of the V1/V2 region does not increase the accessibility of the V3 region of recombinant gp125.
    Sourial S; Nilsson C; Wärnmark A; Achour A; Harris RA
    Curr HIV Res; 2006 Apr; 4(2):229-37. PubMed ID: 16611061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conformational preferences of the HIV-1 principal neutralizing determinant.
    Andrianov AM
    J Biomol Struct Dyn; 2005 Dec; 23(3):267-82. PubMed ID: 16218754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.